Avantor, Inc.

NYSE:AVTR

Medical - Instruments & Supplies

Healthcare
$15.37 +0.69%

+$0.07 today

Market cap
$10.41B
Beta
0.96
P/E (TTM)
-11.7
EPS (TTM)
-$0.81
52W Low $7.27High $15.93

Volume 5.94M

Average 9.44M

AVTR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Avantor, Inc.NYSE: AVTR

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin narrows to 31.7%

Gross margin was 31.7% in Q2 FY2026, down 1.2 pp from a year earlier. On a trailing-twelve-month basis it was 31.8%, down 1.4 pp year over year. Over 3 fiscal years it narrowed by 2.0 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
31.7%+0.1 pp QoQ
Last fiscal yearDec 2025
32.7%-0.9 pp YoY
LTMJun 2026
31.8%-1.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.2 pp——
1 year-0.9 pp——
3 years-2.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
32.7%
Year-over-year change
-0.9pp

Gross Margin vs competitors

How AVTR compares with its peers on the latest reported figures

  • AVTR's LTM Jun 2026 gross margin of 31.8% is the 8th highest of the 9 companies compared; the peer median is 47.6%.
  • Its year-over-year change of -1.4 pp is the 6th highest of 9, against a peer median of -0.6 pp.
  • Over three fiscal years its change of -2.0 pp compares with a peer median of -3.5 pp.
AVTR Competitors Peer median
Gross Margin for AVTR and competitors
Company Period LTM level YoY 3-year change
BLFSBioLife Solutions, Inc.LTM Mar 202663.9% -19.5 pp+3.0 pp
DHRDanaher CorporationLTM Sep 202658.6% -2.7 pp+0.2 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202651.9% -0.9 pp-3.9 pp
RGENRepligen CorporationLTM Jun 202651.1% +6.8 pp-9.8 pp
AZTAAzenta, Inc.LTM Sep 202644.2% -2.0 pp+9.2 pp
WSTWest Pharmaceutical Services, Inc.LTM Jun 202636.8% +1.4 pp-3.6 pp
CRLCharles River Laboratories International, Inc.LTM Jun 202632.2% -0.2 pp-6.3 pp
AVTRAvantor, Inc.LTM Jun 202631.8% -1.4 pp-2.0 pp
STVNStevanato Group S.p.A.LTM Jun 202629.2% +1.1 pp-3.5 pp
Peer median (excluding AVTR) 47.6%-0.6 pp-3.5 pp

Competitors are the stored peer set for AVTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.39B7.51B6.97B6.78B6.55B
Cost of Revenue4.88B4.91B4.6B4.5B4.41B
Gross Profit2.5B2.6B2.36B2.28B2.14B
Gross Margin33.9%34.6%33.9%33.6%32.7%
Research & Development00000
Selling, General & Admin1.53B1.47B1.51B1.64B1.6B
Operating Expenses1.53B1.47B1.67B1.19B2.39B
Depreciation & Amortization379.2M405.5M402.3M405.5M410.2M
EBITDA1.35B1.52B1.1B1.48B138.7M
EBITDA Margin18.3%20.3%15.8%21.8%2.1%
Operating Income972.2M1.13B696.4M1.08B(246.2M)
Operating Margin13.2%15.0%10.0%16.0%-3.8%
Interest Income00000
Interest Expense217.4M265.8M284.8M218.8M169.8M
Other Income / Expenses(219.2M)(279.1M)(285.9M)(230.9M)(195.1M)
Income Before Tax753M851.1M410.5M853.9M(441.3M)
Pre-Tax Margin10.2%11.3%5.9%12.6%-6.7%
Income Tax Expense180.4M164.6M89.4M142.4M88.9M
Net Income572.6M686.5M321.1M711.5M(530.2M)
Net Margin7.8%9.1%4.6%10.5%-8.1%
EPS (Basic)0.861.020.481.05(0.78)
EPS (Diluted)0.851.010.471.04(0.78)
Weighted Avg Shares590.5M650.9M675.6M680.3M678M
Weighted Avg Shares (Diluted)599.6M679.4M678.4M681.9M679.3M

Avantor, Inc.

NYSE:AVTR

Intrinsic Alpha fair value

Locked

Current Price

$15.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.